Skip to main content
. Author manuscript; available in PMC: 2022 Dec 4.
Published in final edited form as: Int J Med Inform. 2020 Aug 7;142:104245. doi: 10.1016/j.ijmedinf.2020.104245

Table 5.

Preventive health screenings stratified by gender identity categories

Cervical cancer screening
Cisgender Women n =
34,027
Cisgender Men n =
114
Transgender Women n =
13
Transgender Men n = 99 Other n = 763 Not Disclosed/ Unknown n =
4,959
X 2
(df)
P-value


FQHC 1 (n = 2,822) Screened n (%) 1,461 (54%) 1 (33%) 1 (25%) 1 (100%) 32 (35%) 0.0009+
Not Screened n 1262 2 3 0 59
FQHC 2 (n = 12,977) Screened n (%) 6,933 (64%) 0 (0%) 41 (59%) 7 (47%) 1,094 (55%) 57.0991 (4) < .0001++
Not Screened n 3979 4 29 8 885
FQHC 3 (n = 13,488) Screened n (%) 8,112 (75%) 22 (54%) 5 (28%) 4 (44%) 1,786 (70%) 50.1116 (4) < .0001++
Not Screened n 2771 19 13 5 751
FQHC 4 (n = 2,803) Screened n (%) 1,446 (53%) 8 (62%) 1 (33%) 0 (0%) 28 (35%) 0.005+
Not Screened n 1260 5 2 1 52
FQHC 5 (n = 8,154) Screened n (%) 4,164 (61%) 26 (46%) 2 (40%) 7 (88%) 376 (51%) 157 (58%) < .0001+
Not Screened n 2639 31 3 1 361 115
Tobacco use: screening and cessation intervention
Cisgender Women n =
34,548
Cisgender Men n =
23,000
Transgender Women n =
173
Transgender Men n =
176
Other n =
677
Not Disclosed/Unknown n =
9,871
X 2
(df)
P-value


FQHC 1 (n = 2,890) Screened n (%) 1,847 (97%) 833 (90%) 0 (0%) 1 (100%) 53 (88%) < .0001+
Not Screened n 54 94 1 0 7
FQHC 2 (n = 27,254) Screened n (%) 13,050 (94%) 8,022 (90%) 138 (91%) 105 (95%) 32 (97%) 3,611 (88%) 161.0507 (5) < .0001++
Not Screened n 903 890 14 5 1 483
FQHC 3 (n = 25,084) Screened n (%) 11,509 (84%) 4,965 (72%) 38 (73%) 16 (80%) 4,257 (84%) 498.8324 (4) < .0001++
Not Screened n 2184 1977 14 4 840
FQHC 4 (n = 4,360) Screened n (%) 2,753 (99%) 1,462 (98%) 6 (100%) 7 (100%) 1 (100%) 83 (97%) 0.0245+
Not Screened n 21 24 0 0 0 3
FQHC 5 (n = 8,137) Screened n (%) 1,955 (88%) 4,329 (91%) 12 (86%) 5 (83%) 552 (89%) 473 (89%) 26.6029 (5) < .0001++
Not Screened n 272 404 2 1 71 61
Screening for clinical depression and follow-up plan
Cisgender Women n =
31,662
Cisgender Men n =
25,027
Transgender Women n =
164
Transgender Men n =
155
Other n =
1,486
Not Disclosed/Unknown n =
13,077
X 2 (df) P-value


FQHC 1 (n = 5,212) Screened n (%) 2,536 (81%) 1,451 (79%) 6 (75%) 4 (100%) 1 (50%) 121 (57%) < .0001+
Not Screened n 602 397 2 0 1 91
FQHC 2 (n = 23,161) Screened n (%) 8,887 (88%) 7,009 (89%) 125 (93%) 78 (87%) 33 (89%) 3,037 (61%) 2146.8855 (5) < .0001++
Not Screened n 1177 835 10 12 4 1954
FQHC 3 (n = 24,394) Screened n (%) 9,999 (87%) 5,329 (86%) 3 (100%) 37 (73%) 9 (64%) 4,847 (73%) < .0001+
Not Screened n 1529 863 0 14 5 1759
FQHC 4 (n = 4,333) Screened n (%) 2,273 (97%) 1,570 (96%) 3 (100%) 1 (50%) 1 (100%) 318 (89%) < .0001+
Not Screened n 67 59 0 1 0 40
FQHC 5 (14,471) Screened n (%) 4,048 (88%) 6,680 (89%) 14 (93%) 8 (100%) 1,260 (88%) 816 (90%) 4.4998 (5) 0.4799++
Not Screened n 544 834 1 0 172 94
+

Fisher’s Exact Test

++

Chi-square Test; FQHC = federally qualified health center; – = No patients reported